Innovative contracts can offer significant benefits for stakeholders delivering novel drugs and medical products to patients — but they require resources to design and implement. This Implementation Brief outlines key … Read More
Implementation Brief: Innovative contracting 101
This brief provides an introduction to innovative contracts, or value-based contracts, which may be used to facilitate access to innovative, high-cost treatments. These contracts can address uncertainty around treatments and … Read More
Implementation Brief: Access considerations for innovative treatments
This brief offers a checklist of key steps that different stakeholders should consider to ensure patients have access to innovative treatments. These therapies present unique challenges for different stakeholders and … Read More
Implementation Brief: Key terms for payment innovation
This brief provides definitions of key terms that are often used in discussions about designing and implementing innovative payment solutions. It offers an overview of solution models, types of risk, … Read More
Implementation Brief: Considerations for developers in applying the Multiple Best Price (MBP) rule to improve access to novel therapies
This brief highlights some key steps and considerations for biopharmaceutical developers of novel, high-value therapies seeking to successfully implement CMS’s Multiple Best Price rule. The rule, which went into effect … Read More
Implementation Brief: Understanding access issues for new therapies
Our first implementation brief outlines several major barriers to patient access for novel cell and gene therapies. It also describes how providers, payers, and developers may overcome these barriers, with … Read More
Are Cell and Gene Therapy programs a better bet?
Compared to traditional drug development programs, do durable cell and gene therapy (CGT) programs experience higher or lower clinical success rates? Estimating the Probability of Technical and Regulatory Success (PTRS) … Read More
Innovating methods for planning, producing, and using real-world evidence
Real-world data (RWD) are a critical element of the evidence needed to help reach this goal, potentially informing a new drug’s development or providing insight for its use after it … Read More
Payer and developer perspectives on alternative payment models
Expert Review of Pharmacoeconomics & Outcomes Research, Volume 24, 2024 – Issue 2Moradian, R., Meshesha, T., Trusheim, M., & Barlow, J. F. The paper reports the results of a survey … Read More
How can self-insured employers prepare for the portfolio impact of highcost gene therapies coming to market?
Self-insured employers (SIEs) currently rely on traditional stop-loss insurance to protect against unexpected high-cost claims, including those for cell and gene therapies. Given that current approvals are in rare diseases, … Read More